Continuous Glucose Monitoring Device Market Size, Share, Growth, and Industry Analysis, By Type (Sensors, Transmitters & Receivers), By Application (TYPE1 Diabetes, TYPE2 Diabetes, Others), Regional Insights and Forecast to 2035

Continuous Glucose Monitoring Device Market Overview

The global Continuous Glucose Monitoring Device Market size estimated at USD 10692.76 million in 2026 and is projected to reach USD 28101.22 million by 2035, growing at a CAGR of 11.34% from 2026 to 2035.

The global Continuous Glucose Monitoring Device Market is witnessing strong expansion due to the increasing diabetic population, rising adoption of wearable healthcare technologies, and growing awareness regarding real-time glucose tracking. More than 537 million adults were living with diabetes in 2024, while over 240 million individuals remained undiagnosed globally. Continuous glucose monitoring devices are increasingly replacing traditional fingerstick blood glucose systems, with nearly 41% of insulin-dependent diabetic patients using CGM systems regularly. Sensor-based monitoring devices accounted for approximately 68% of product adoption across hospitals and homecare settings. More than 74% of endocrinologists recommended CGM integration for diabetes management in advanced healthcare systems during 2025.

The United States represents the largest market for continuous glucose monitoring devices due to the high prevalence of obesity and diabetes. More than 38 million Americans were diagnosed with diabetes in 2025, while approximately 98 million adults were identified with prediabetes. Around 64% of Type 1 diabetes patients in the United States actively used CGM devices for glucose management. Medicare coverage expansion increased CGM adoption by nearly 29% among elderly patients. Hospitals and outpatient diabetes centers in the United States reported over 72% preference for wearable glucose sensors over conventional monitoring methods. Smartphone-connected CGM systems were used by approximately 61% of diabetic adults aged between 20 and 45 years.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Nearly 64% of insulin-dependent diabetic patients shifted toward continuous glucose monitoring systems, while real-time monitoring reduced hypoglycemic episodes by 38% and improved glucose control efficiency by 41% across chronic diabetic populations.
• Major Market Restraint: Around 47% of low-income diabetic patients reported affordability concerns, while 36% of healthcare facilities in developing economies experienced reimbursement limitations and 28% of users discontinued CGM adoption due to sensor replacement costs.
• Emerging Trends: Approximately 58% of new CGM products introduced during 2025 featured smartphone integration, while wearable patch-based sensors gained 44% adoption and AI-enabled glucose prediction functions improved patient monitoring accuracy by 33%.
• Regional Leadership: North America accounted for nearly 42% market share due to higher diabetes awareness, Europe represented 27%, Asia-Pacific reached 22%, and Middle East & Africa contributed close to 9% market penetration globally.
• Competitive Landscape: The top five manufacturers controlled approximately 76% of the global Continuous Glucose Monitoring Device Market, while integrated sensor platforms represented 63% of competitive product launches during 2024 and 2025.
• Market Segmentation: Sensors held nearly 69% market share among product types, while Type 2 diabetes applications contributed approximately 52% demand owing to increased diabetic monitoring requirements and growing wearable healthcare acceptance.
• Recent Development: More than 46% of newly launched CGM devices included extended wear duration above 14 days, while calibration-free systems improved patient convenience by 39% and enhanced glucose tracking compliance by 34%.

Continuous Glucose Monitoring Device Market Latest Trends

The Continuous Glucose Monitoring Device Market is experiencing major transformation due to technological advancements and rising wearable healthcare adoption. More than 71% of newly introduced devices during 2025 featured Bluetooth-enabled wireless connectivity for smartphone integration. Sensor miniaturization improved patient comfort by approximately 36%, while disposable wearable sensors gained nearly 49% consumer preference across homecare applications. Artificial intelligence integration into CGM systems increased glucose prediction efficiency by 31%, helping physicians identify critical glycemic events earlier.

Factory-calibrated sensors represented approximately 62% of total product installations due to their ease of use and reduced fingerstick dependency. Remote patient monitoring applications expanded by nearly 43%, particularly among elderly diabetic populations requiring continuous supervision. Pediatric diabetes monitoring also increased substantially, with around 28% of children diagnosed with Type 1 diabetes using CGM systems regularly in 2025. Smartwatch-compatible CGM platforms witnessed 39% growth in consumer adoption because of increased health-tracking awareness. Healthcare providers increasingly recommend real-time continuous monitoring systems, with nearly 74% of endocrinologists preferring CGM devices over traditional glucose meters. Cloud-connected healthcare monitoring platforms improved physician-patient data sharing by 46%. Additionally, long-duration wearable sensors capable of operating continuously for 15 days gained 33% higher adoption than shorter-duration products. Online pharmacy distribution channels accounted for nearly 29% of total CGM device sales globally due to increased digital healthcare accessibility.

Continuous Glucose Monitoring Device Market Dynamics

DRIVER

" Rising prevalence of diabetes and obesity worldwide."

The increasing global diabetic population remains the strongest growth driver for the Continuous Glucose Monitoring Device Market. More than 537 million adults worldwide were diagnosed with diabetes during 2025, while obesity prevalence exceeded 39% among adults in several developed economies. Approximately 61% of diabetic patients required regular glucose monitoring due to insulin dependency and chronic metabolic complications. Real-time glucose monitoring reduced severe hypoglycemia events by 38%, encouraging healthcare providers to recommend CGM systems extensively. Hospital admissions related to diabetes complications increased by nearly 24% globally, accelerating preventive monitoring demand. Government healthcare organizations expanded diabetes screening programs by 31%, improving CGM awareness among high-risk populations. Wearable health technology adoption also rose significantly, with approximately 57% of patients preferring non-invasive or minimally invasive monitoring devices. Integration of smartphone applications improved patient engagement by 42%, further supporting product adoption.

RESTRAINT

" High device costs and reimbursement limitations."

Despite increasing adoption, affordability remains a critical restraint for the Continuous Glucose Monitoring Device Market. Approximately 47% of diabetic patients in middle-income economies reported financial limitations associated with CGM systems. Sensor replacement requirements every 10 to 15 days increased long-term operational costs substantially. Nearly 36% of healthcare insurers in developing regions provided partial reimbursement for CGM products, restricting patient accessibility. Hospitals in rural healthcare systems experienced approximately 29% lower CGM deployment rates because of procurement budget limitations. Technical maintenance and calibration training requirements also created operational challenges for healthcare providers. Around 22% of first-time users discontinued device usage within six months because of maintenance complexity and recurring sensor expenses. Additionally, import dependency for advanced sensor technologies increased product pricing volatility in emerging markets by nearly 18% during 2025.

OPPORTUNITY

" Expansion of remote healthcare and digital monitoring."

The expansion of telehealth and digital healthcare ecosystems creates strong opportunities for the Continuous Glucose Monitoring Device Market. More than 52% of diabetic patients globally participated in remote healthcare consultations during 2025. Integration of CGM systems with cloud-based monitoring platforms improved physician access to patient glucose data by approximately 46%. Remote glucose monitoring reduced emergency diabetic hospitalizations by 27%, encouraging healthcare providers to invest in connected monitoring systems. Home healthcare adoption increased by nearly 44%, particularly among elderly diabetic patients requiring continuous supervision. Artificial intelligence-enabled predictive analytics improved glucose management efficiency by 34%, enabling earlier detection of hypoglycemic risks. Smartphone-linked CGM applications achieved approximately 63% patient preference due to convenience and accessibility. Emerging economies also present substantial opportunities, with diabetic populations in Asia-Pacific increasing by nearly 19% between 2023 and 2025.

CHALLENGE

" Data accuracy concerns and cybersecurity risks."

Maintaining sensor accuracy and protecting patient healthcare data remain major challenges in the Continuous Glucose Monitoring Device Market. Approximately 21% of healthcare providers reported occasional sensor reading inconsistencies during rapid glucose fluctuations. Calibration errors affected around 17% of first-generation monitoring devices used in developing healthcare systems. Patients using intensive insulin therapy required highly accurate monitoring, increasing pressure on manufacturers to enhance sensor precision. Cybersecurity concerns also intensified due to increasing cloud connectivity and smartphone integration. Nearly 33% of healthcare institutions identified patient data protection as a critical challenge for wearable healthcare technologies. Unauthorized data access incidents involving connected healthcare devices increased by approximately 14% globally during 2025. Regulatory compliance requirements became stricter across Europe and North America, increasing certification costs and delaying product approvals for nearly 19% of manufacturers.

Continuous Glucose Monitoring Device Market Segmentation 

The Continuous Glucose Monitoring Device Market is segmented by type and application, with sensors dominating product demand due to recurring replacement requirements and higher patient usage frequency. Sensors contributed approximately 69% market share, while transmitters and receivers accounted for 31% collectively. By application, Type 2 diabetes represented nearly 52% market demand because of the large diabetic population and increasing awareness regarding glucose monitoring. Type 1 diabetes contributed around 39% market share due to mandatory insulin monitoring requirements, while other diabetes-related conditions accounted for approximately 9% adoption globally. Homecare usage exceeded 58% of overall device installations during 2025.

Download Free Sample to learn more about this report.

BY TYPE

Sensors: Sensors represent the largest segment in the Continuous Glucose Monitoring Device Market, accounting for approximately 69% market share during 2025. Sensor demand remains high because replacement cycles occur every 10 to 15 days depending on product type. More than 74% of diabetic patients using CGM systems preferred disposable wearable sensors because of improved comfort and convenience. Waterproof and miniaturized sensors gained nearly 41% higher adoption compared to conventional sensor designs. Advanced sensor technologies improved glucose detection accuracy by approximately 32%, while factory-calibrated sensors reduced manual calibration requirements by 38%. North America accounted for around 44% of global sensor demand due to extensive diabetes monitoring programs and high wearable healthcare adoption.

Transmitters & Receivers: Transmitters and receivers collectively represented approximately 31% of the Continuous Glucose Monitoring Device Market in 2025. Wireless data transmission capabilities improved remote patient monitoring efficiency by nearly 46%. Smartphone-compatible transmitters accounted for around 58% of installations because patients increasingly preferred mobile health integration. Rechargeable transmitters gained approximately 29% higher adoption due to longer operational lifecycles and reduced maintenance requirements. Receivers featuring real-time glucose alerts improved patient response time to hypoglycemic events by nearly 34%. Hospitals and diabetes specialty clinics represented around 49% of receiver installations globally due to advanced monitoring requirements for critical diabetic cases.

BY APPLICATION

TYPE1 Diabetes: Type 1 diabetes applications accounted for approximately 39% market share in the Continuous Glucose Monitoring Device Market during 2025. More than 64% of insulin-dependent Type 1 diabetic patients actively used CGM systems because of the need for continuous glucose monitoring and insulin dose adjustments. Pediatric Type 1 diabetes monitoring increased by approximately 27% due to growing parental awareness regarding advanced diabetic care. Real-time glucose monitoring reduced severe hypoglycemia incidents among Type 1 patients by nearly 38%. Healthcare providers in developed economies recommended CGM systems for around 71% of newly diagnosed Type 1 diabetes patients because of improved glucose management outcomes.

TYPE2 Diabetes: Type 2 diabetes dominated application demand with approximately 52% market share globally. More than 462 million people worldwide were affected by Type 2 diabetes during 2025, significantly increasing demand for glucose monitoring technologies. CGM adoption among Type 2 diabetic patients increased by nearly 34% because of obesity-related health complications and rising healthcare awareness. Wearable glucose monitoring systems improved treatment compliance by approximately 29% among adult diabetic populations. Home-based diabetes management accounted for nearly 57% of Type 2 CGM device installations. Asia-Pacific experienced the fastest Type 2 diabetes monitoring expansion due to urbanization and changing dietary patterns.

Others: Other applications, including gestational diabetes and prediabetes monitoring, accounted for approximately 9% market share during 2025. Gestational diabetes prevalence exceeded 16% among pregnant women in urban healthcare systems, increasing temporary CGM usage. Prediabetic monitoring programs expanded by nearly 24% globally because of preventive healthcare initiatives. Hospitals increasingly utilized CGM systems in intensive care units, where approximately 18% of critically ill diabetic patients required continuous monitoring support. Sports health and metabolic wellness monitoring applications also increased by around 14%, particularly among athletes and fitness-focused consumers seeking glucose optimization insights.

Continuous Glucose Monitoring Device Market Regional Outlook

The Continuous Glucose Monitoring Device Market demonstrates strong regional variation driven by diabetes prevalence, healthcare infrastructure, reimbursement support, and wearable healthcare adoption. North America maintained approximately 42% market share due to advanced diabetic care programs and strong technology penetration. Europe accounted for nearly 27% share supported by government healthcare systems and increasing elderly diabetic populations. Asia-Pacific represented around 22% market demand because of rapidly increasing diabetes prevalence and healthcare digitization. Middle East & Africa contributed close to 9% share due to expanding healthcare investments and rising awareness regarding chronic disease monitoring technologies.

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominated the Continuous Glucose Monitoring Device Market with approximately 42% market share during 2025. The United States accounted for more than 84% of regional demand due to the high prevalence of obesity and diabetes. Over 38 million Americans were diagnosed with diabetes, while nearly 98 million adults remained prediabetic. Continuous glucose monitoring adoption among insulin-dependent diabetic patients exceeded 64%, supported by favorable reimbursement systems and strong healthcare awareness. Medicare expansion policies improved CGM accessibility for elderly diabetic patients by approximately 29%. Hospitals and specialty diabetes centers in North America reported nearly 72% preference for wearable glucose monitoring systems over traditional glucose meters. Smartphone-connected CGM devices represented approximately 61% of consumer usage because of high digital healthcare penetration. Pediatric diabetes monitoring also increased significantly, with around 31% of Type 1 diabetic children using CGM systems regularly. Canada contributed approximately 11% of regional demand, supported by government healthcare initiatives promoting advanced diabetes management technologies. Home healthcare monitoring accounted for nearly 58% of total regional installations, while telehealth-based glucose monitoring expanded by approximately 41%. Sensor replacement demand remained strong due to recurring usage patterns and rising diabetic populations.

EUROPE

Europe accounted for approximately 27% of the global Continuous Glucose Monitoring Device Market during 2025. Germany, the United Kingdom, France, and Italy represented the largest regional adopters due to aging populations and strong healthcare infrastructure. More than 61 million adults across Europe were living with diabetes, while approximately 44% of diabetic patients required regular glucose monitoring. Government-funded healthcare systems significantly supported CGM adoption across European countries. Around 57% of Type 1 diabetic patients in Western Europe used continuous glucose monitoring systems for real-time glucose tracking. Sensor-based wearable technologies gained approximately 36% higher adoption compared to traditional monitoring solutions due to patient convenience and improved healthcare outcomes. Remote patient monitoring expanded substantially across Europe, with telehealth integration improving glucose data accessibility by nearly 42%. Germany represented approximately 24% of regional market demand due to advanced diabetic care facilities and strong reimbursement policies. France and the United Kingdom collectively contributed around 33% of regional installations. Calibration-free sensors accounted for nearly 59% of device adoption because patients preferred low-maintenance glucose monitoring systems.

ASIA-PACIFIC

Asia-Pacific represented approximately 22% of the Continuous Glucose Monitoring Device Market during 2025 and remained the fastest-growing regional market due to rapidly increasing diabetes prevalence. China and India collectively accounted for more than 54% of regional diabetic populations. Urbanization and changing dietary habits contributed significantly to rising obesity rates across Asia-Pacific healthcare systems. China represented approximately 39% of regional CGM demand due to its diabetic population exceeding 140 million adults. Smartphone-compatible monitoring systems gained nearly 44% higher adoption among urban consumers because of increasing digital healthcare awareness. India experienced strong market expansion, with diabetic cases exceeding 101 million adults in 2025. Government diabetes screening initiatives increased glucose monitoring awareness by approximately 28%. Japan and South Korea maintained advanced CGM technology adoption rates due to strong healthcare infrastructure and aging populations. Around 48% of diabetic patients in Japan preferred wearable monitoring systems with real-time glucose alerts. Online healthcare distribution channels contributed nearly 31% of regional device sales because digital commerce platforms improved accessibility.

MIDDLE EAST & AFRICA

The Middle East & Africa accounted for approximately 9% of the global Continuous Glucose Monitoring Device Market during 2025. Gulf countries represented the largest regional adopters due to high obesity prevalence and increasing healthcare investments. Saudi Arabia and the United Arab Emirates collectively contributed nearly 46% of regional CGM demand because diabetes prevalence exceeded 18% among adults in urban populations. Healthcare digitization programs across the Gulf region increased wearable healthcare adoption by approximately 33%. Hospitals and diabetes specialty clinics accounted for nearly 62% of total CGM installations due to centralized healthcare systems. Smartphone-connected glucose monitoring devices gained approximately 27% higher consumer adoption among younger diabetic patients. South Africa represented one of the leading African markets due to expanding private healthcare infrastructure and rising diabetic awareness. Government healthcare campaigns improved diabetes screening participation by nearly 21% during 2025. However, affordability remained a challenge, with approximately 49% of diabetic patients lacking access to advanced glucose monitoring technologies.

List of Top Continuous Glucose Monitoring Device Companies

• Abbott
• Dexcom
• Medtronic
• Senseonics
• YUYUE MEDICAL
• MicroTech Medical

List of Top 2 Companies Market Share

Abbott: Abbott accounted for approximately 32% global market share during 2025, supported by strong adoption of wearable glucose monitoring sensors and expansion across more than 60 healthcare markets worldwide.

Dexcom: Dexcom represented nearly 27% market share globally, driven by smartphone-connected CGM systems, advanced sensor accuracy exceeding 90%, and growing adoption among Type 1 diabetic populations.

Investment Analysis and Opportunities

The Continuous Glucose Monitoring Device Market continues attracting strong investment due to increasing diabetes prevalence and rising wearable healthcare demand. Global healthcare organizations increased digital diabetes management investments by approximately 36% during 2025. Sensor manufacturing facilities expanded significantly across Asia-Pacific, reducing production dependency on imported components by nearly 22%. Venture capital funding for wearable glucose monitoring technologies increased by approximately 31%, particularly for non-invasive sensor development projects. Artificial intelligence integration into CGM platforms created substantial opportunities for predictive healthcare monitoring. AI-supported glucose prediction technologies improved diabetic management efficiency by approximately 34%, encouraging investments from medical technology firms. Remote healthcare infrastructure expansion also generated opportunities for cloud-connected CGM platforms, with telehealth-linked monitoring systems increasing by nearly 41% globally.

Emerging economies represent significant growth opportunities because diabetic populations continue rising rapidly. India and China collectively added more than 28 million new diabetic patients between 2023 and 2025. Government-funded diabetes awareness programs increased glucose monitoring adoption by approximately 26% across urban healthcare systems. Pediatric diabetes management and gestational diabetes monitoring also present untapped opportunities due to increasing preventive healthcare awareness. Research institutions invested heavily in long-duration wearable sensors capable of operating continuously for 20 days. Non-invasive optical glucose monitoring technologies received approximately 18% higher research funding during 2025 compared to traditional invasive monitoring systems. These advancements continue creating long-term investment opportunities across hospitals, homecare, and telemedicine healthcare ecosystems.

New Product Development

New product development within the Continuous Glucose Monitoring Device Market focuses heavily on sensor accuracy, wear duration, miniaturization, and smartphone connectivity. More than 46% of newly launched CGM products during 2025 featured extended sensor wear duration exceeding 14 days. Manufacturers improved sensor precision by approximately 29%, helping reduce glucose reading discrepancies during rapid glycemic fluctuations. Smartphone-compatible monitoring platforms accounted for nearly 63% of new product introductions because patients increasingly preferred mobile healthcare integration. Bluetooth-enabled transmitters improved real-time data transmission efficiency by approximately 38%. Waterproof wearable sensors gained substantial popularity, with consumer adoption increasing by nearly 34% among active diabetic patients and athletes.

Artificial intelligence integration became a major development priority across the industry. AI-supported glucose prediction systems improved early hypoglycemia detection rates by approximately 32%, enhancing patient safety. Pediatric-focused CGM devices featuring smaller sensors and painless insertion systems gained around 21% higher adoption among children diagnosed with Type 1 diabetes. Several companies also focused on non-invasive monitoring technologies using optical and laser-based glucose sensing methods. Research investments in needle-free glucose monitoring increased by approximately 27% during 2025. Rechargeable transmitters with battery lifecycles exceeding 12 months improved device durability and reduced replacement frequency by nearly 24%. Cloud-connected healthcare integration further enhanced physician accessibility to patient glucose data, improving treatment response efficiency.

Five Recent Developments (2023-2025)

• Abbott introduced an advanced CGM sensor with 15-day wear duration during 2024, improving patient monitoring continuity by approximately 33%.
• Dexcom launched a smartphone-integrated CGM platform in 2025 featuring predictive glucose alerts with nearly 31% faster hypoglycemia detection capability.
• Medtronic expanded automated insulin delivery integration with CGM systems during 2024, improving glucose management efficiency by approximately 28% among insulin-dependent patients.
• Senseonics enhanced implantable glucose monitoring technology in 2025 with sensor operational duration exceeding 180 days and patient satisfaction increasing by nearly 26%.
• YUYUE MEDICAL increased production capacity for wearable glucose monitoring sensors during 2024 by approximately 37% to support rising demand across Asia-Pacific healthcare markets.

Report Coverage of Continuous Glucose Monitoring Device Market

The Continuous Glucose Monitoring Device Market report provides comprehensive analysis covering market dynamics, technological developments, segmentation trends, competitive landscape, and regional performance across global healthcare systems. The report evaluates more than 25 countries and analyzes diabetic population distribution, wearable healthcare adoption, and healthcare infrastructure expansion. Approximately 537 million diabetic adults globally formed the primary patient base evaluated within the report coverage framework. The report includes detailed segmentation analysis by type, including sensors, transmitters, and receivers, alongside application-based evaluation covering Type 1 diabetes, Type 2 diabetes, and other diabetic conditions. Sensors represented approximately 69% market share during 2025 and remained the dominant product category analyzed extensively within the report. Type 2 diabetes applications accounted for nearly 52% of market demand because of increasing obesity prevalence and rising diabetic populations.

Regional analysis within the report covers North America, Europe, Asia-Pacific, and Middle East & Africa, focusing on healthcare infrastructure, reimbursement systems, wearable technology penetration, and diabetic awareness initiatives. North America maintained approximately 42% market share due to advanced healthcare adoption and favorable reimbursement structures. Asia-Pacific emerged as the fastest-expanding regional market because diabetic populations increased rapidly across China and India. The report further analyzes competitive strategies, product innovation activities, regulatory compliance requirements, and investment patterns across leading manufacturers including Abbott, Dexcom, Medtronic, Senseonics, YUYUE MEDICAL, and MicroTech Medical. It also evaluates remote healthcare integration, artificial intelligence adoption, cloud-connected monitoring systems, and next-generation non-invasive glucose monitoring technologies shaping future industry expansion.